All thyroid cancer patients ask about TSH control goals for post-operative transplantation therapy for thyroid cancer, and this article is written to provide a general overview.
Suppressive therapy for thyroid cancer is very important to suppress postoperative recurrence. According to the guidelines, patients with differentiated thyroid cancer are divided into two groups: high-risk and low-risk.
The high-risk group includes.
1. aged <15 years or >45 years.
2. male.
3. nodules >4 cm in diameter.
4, extra-thyroidal invasion.
5. History of radiation exposure.
6. Thyroid cancer-related disease.
7. Positive margins.
8, distant metastasis
9. Extensive metastatic lymph node invasion in the lymph node envelope of the neck.
Low risk group includes.
1, 15 years < age < 45 years.
2, nodule diameter <4cm.
3. No history of radiation exposure.
4. No thyroid cancer-related disease.
5. Negative margins.
6. No distant metastasis.
7. No lymph node metastasis in the neck.
8. No other invasive variants. For the high-risk group, the guidelines recommend taking thyroxine preparations so that TSH is <0,1 mU/L; for the low-risk group, 0,1 < mU/L TSH <0,3 mU/L; and for the multi-year low-risk group, 0,3 mU/L.
The overall 10-year survival rate of differentiated thyroid cancer can reach 90%. According to the aforementioned high- and low-risk staging, its 20-year survival rate: low-risk is about 90% and high-risk is about 61%. Even with distant metastases, the 10-year survival rate of differentiated thyroid cancer can be 25%-40%.